STRO vs. AXGN

Last updated Jun 23, 2026

STRO (Sutro Biopharma, Inc.) and AXGN (AxoGen, Inc.) are both stocks. Both are in the Healthcare sector — STRO in Biotechnology, AXGN in Medical Devices. Over the past 5 years, STRO returned -29.85%/yr vs 15.47%/yr for AXGN. At a 0.26 correlation, their price movements are largely independent.

Performance

STRO vs. AXGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sutro Biopharma, Inc. (STRO) and AxoGen, Inc. (AXGN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, STRO achieves a 172.69% return, which is significantly higher than AXGN's 37.34% return.

STRO

• 1D: 6.48%
• 1M: 23.39%
• YTD: 172.69%
• 6M: 204.24%
• 1Y: 293.93%
• 3Y*: -14.85%
• 5Y*: -29.85%
• 10Y*: —

AXGN

• 1D: 0.25%
• 1M: 9.90%
• YTD: 37.34%
• 6M: 37.29%
• 1Y: 361.97%
• 3Y*: 71.00%
• 5Y*: 15.47%
• 10Y*: 21.87%

*Multi-year figures are annualized to reflect compound growth (CAGR)

STRO vs. AXGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
STRO Sutro Biopharma, Inc.	172.69%	-37.12%	-57.11%	-46.91%	-45.70%	-31.46%	97.36%	21.95%	-40.34%
AXGN AxoGen, Inc.	37.34%	98.60%	141.29%	-31.56%	6.51%	-47.65%	0.06%	-12.43%	-42.85%

Correlation

The correlation between STRO and AXGN is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.15
Correlation (3Y) Calculated over the trailing 3-year period	0.24
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (All Time) Calculated using the full available price history since Sep 27, 2018	0.26

The correlation between STRO and AXGN shifts across timeframes, from 0.15 (1 year) to 0.27 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap STRO : $412.75M AXGN : $2.32B
EPS STRO : -$15.91 AXGN : -$0.66
PS Ratio STRO : 3.06 AXGN : 8.97
Total Revenue (TTM) STRO : $99.61M AXGN : $238.11M
Gross Profit (TTM) STRO : $83.46M AXGN : $178.61M
EBITDA (TTM) STRO : -$105.17M AXGN : $5.69M

Return for Risk

STRO vs. AXGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

STRO

STRO Risk / Return Rank: 93
STRO Sharpe Ratio Rank: 96
STRO Sortino Ratio Rank: 91
STRO Omega Ratio Rank: 88
STRO Calmar Ratio Rank: 96
STRO Martin Ratio Rank: 95

AXGN

AXGN Risk / Return Rank: 99
AXGN Sharpe Ratio Rank: 99
AXGN Sortino Ratio Rank: 99
AXGN Omega Ratio Rank: 98
AXGN Calmar Ratio Rank: 99
AXGN Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

STRO vs. AXGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sutro Biopharma, Inc. (STRO) and AxoGen, Inc. (AXGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	STRO	AXGN	Difference
Sharpe ratio: Return per unit of total volatility	3.30	6.81	-3.51
Sortino ratio: Return per unit of downside risk	3.26	6.02	-2.75
Omega ratio: Gain probability vs. loss probability	1.39	1.76	-0.37
Calmar ratio: Return relative to maximum drawdown	7.35	18.90	-11.55
Martin ratio: Return relative to average drawdown	18.71	65.69	-46.98

STRO vs. AXGN - Sharpe Ratio Comparison

The current STRO Sharpe Ratio is 3.30, which is lower than the AXGN Sharpe Ratio of 6.81. The chart below compares the historical Sharpe Ratios of STRO and AXGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

STRO vs. AXGN - Drawdown Comparison

The maximum STRO drawdown since its inception was -98.10%, roughly equal to the maximum AXGN drawdown of -98.49%. Use the drawdown chart below to compare losses from any high point for STRO and AXGN.

Drawdown Indicators

	STRO	AXGN	Difference
Max Drawdown Largest peak-to-trough decline	-98.10%	-98.49%	+0.39%
Max Drawdown (1Y) Largest decline over 1 year	-40.28%	-19.30%	-20.98%
Max Drawdown (3Y) Largest decline over 3 years	-90.72%	-61.02%	-29.70%
Max Drawdown (5Y) Largest decline over 5 years	-97.77%	-83.69%	-14.08%
Max Drawdown (10Y) Largest decline over 10 years	—	-93.54%	—
Current Drawdown Current decline from peak	-88.54%	-19.59%	-68.95%
Average Drawdown Average peak-to-trough decline	-61.39%	-64.83%	+3.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.79%	5.54%	+10.25%

Volatility

STRO vs. AXGN - Volatility Comparison

Sutro Biopharma, Inc. (STRO) has a higher volatility of 34.12% compared to AxoGen, Inc. (AXGN) at 11.38%. This indicates that STRO's price experiences larger fluctuations and is considered to be riskier than AXGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	STRO	AXGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	34.12%	11.38%	+22.74%
Volatility (6M) Calculated over the trailing 6-month period	62.48%	33.36%	+29.12%
Volatility (1Y) Calculated over the trailing 1-year period	90.02%	53.70%	+36.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	88.34%	64.07%	+24.27%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	85.41%	62.09%	+23.32%

Dividends

STRO vs. AXGN - Dividend Comparison

Neither STRO nor AXGN has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both STRO and AXGN in my portfolio?

STRO and AXGN have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, STRO or AXGN?

STRO has higher volatility (34.12%) compared to AXGN (11.38%). In terms of maximum drawdown, STRO dropped -98.10% vs AXGN's -98.49%.

Which has better risk-adjusted returns?

AXGN currently has the higher Sharpe Ratio (6.81 vs 3.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.